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Abstract
Background: Observational studies suggest an increased risk of eczema in children 
living in hard versus soft water areas, and there is, therefore, an interest in know-
ing whether softening water may prevent eczema. We evaluated the feasibility of 
a parallel- group assessor- blinded pilot randomized controlled trial to test whether 
installing a domestic ion- exchange water softener before birth in hard water areas 
reduces the risk of eczema in infants with a family history of atopy.
Methods: Pregnant women living in hard water areas (>250 mg/L calcium carbonate) 
in and around London UK, were randomized 1:1 antenatally to either have an ion- 
exchange water softener installed in their home or not (ie to continue to receive usual 
domestic hard water). Infants were assessed at birth and followed up for 6 months. 
The main end- points were around feasibility, the primary end- point being the pro-
portion of eligible families screened who were willing and able to be randomized. 
Clinical end- points were evaluated including frequency of parent- reported doctor- 
diagnosed eczema and visible eczema on skin examination. Descriptive analyses were 
conducted, and no statistical testing was performed as this was a pilot study.
Results: One hundred and forty- nine families screened were eligible antenatally and 
28% (41/149) could not have a water softener installed due to technical reasons or lack 
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
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1  |  INTRODUC TION
Eczema (syn. atopic eczema, atopic dermatitis) is a common inflam-
matory skin condition affecting around 20% of UK children.1 It is 
associated with significant morbidity and affects health- related 
quality of life. The cause of eczema is not fully understood. It is 
likely to be multifactorial, and several genetic and environmen-
tal factors have been identified.2 No primary prevention strat-
egy has been established.3 However, several approaches have 
been proposed such as probiotics during pregnancy, dietary 
of landlord approval. Eighty of 149 (54%) were randomized, the primary end- point. 
Two participants withdrew immediately after randomization, leaving 39 participants in 
each arm (78 total). Attrition was 15% (12/78) by 6 months postpartum. All respond-
ents (n = 69) to the study acceptability questionnaire reported that the study was ac-
ceptable. Fifty- six of 708 (7.9%) water samples in the water softener arm were above 
the hard water threshold of 20 mg/L CaCO3. At 6 months of age 27/67 infants (40%) 
developed visible eczema, 12/36 (33%) vs. 15/31 (48%) in the water softener and con-
trol groups, respectively, difference −15% (95% CI −38, 8.3%), with most assessments 
(≥96%) remaining blinded. Similarly, a lower proportion of infants in the water softener 
arm had parent- reported, doctor- diagnosed eczema by 6 months compared to the 
control arm, 6/17 (35%) versus 9/19 (47%), difference −12% (95% CI −44, 20%).
Conclusion: A randomized controlled trial of water softeners for the prevention of 
atopic eczema in high- risk infants is feasible and acceptable.
K E Y W O R D S
atopic eczema, hard water, prevention trial, water softener
G R A P H I C A L  A B S T R A C T
In the SOFTER trial, approximately half of eligible families were willing and able to be randomized to a water softener. There were less 
infants that had visible or parent- reported doctor- diagnosed eczema in the water softener group in comparison with the control group, 
which had their usual hard domestic water supply. Lastly, this pilot trial showed that a trial of water softeners for preventing eczema in high- 
risk infants is feasible and acceptable.
Figure created with biorender
Key Messages
• Approximately half of the eligible families were willing 
and able to be randomized.
• Less infants in the water softener arm developed a visible 
eczema or parent- reported doctor- diagnosed eczema.
• An RCT of water softeners for preventing eczema in 
high- risk infants is feasible and acceptable.
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supplementation, house dust mite avoidance, intensive emollient 
use and domestic water softening.4
Hard water is the result of dissolved minerals, mainly calcium 
carbonate and magnesium carbonate, from the percolation of water 
through rock in the environment. England, especially the south, has 
very hard (>250 mg/L calcium carbonate) domestic water. A cross- 
sectional study conducted in the 1990s found that primary school- 
aged children living in hard water areas had an increased risk of 
eczema, compared to children living in softer water areas around 
Nottingham, UK.5 Two further cross- sectional studies amongst 
school children conducted in Japan and Spain confirmed this associ-
ation.6,7 Subsequently, a cross- sectional analysis from a cohort study 
amongst over 1300 infants in England and Wales has also confirmed 
this relationship in early life, even after adjusting for likely confound-
ers.8 The same study suggested a possible interaction with loss- of- 
function mutations in the skin barrier gene, filaggrin (FLG). Most 
recently, a large study from a Danish birth cohort found a 5% in-
crease in the prevalence of eczema within the first 18 months of life 
for each 5 unit increase in domestic water hardness (equivalent to 
89.2 mg/L calcium carbonate)9 over a range of 6.60– 35.90 German 
degrees of hardness [118– 641 mg/L calcium carbonate]).10
Several potential mechanisms have been proposed for how hard 
water may lead to eczema development: increased deposition of de-
tergents such as sodium lauryl sulphate (SLS) on the skin, altered 
calcium signalling in the epidermis, and a rise in skin surface pH, re-
sulting in increased protease activity could all have a detrimental ef-
fect on skin barrier function.8 Experimental work has demonstrated 
an increased deposition of SLS in skin washed with hard water ver-
sus softened water.11 In animal studies using a hairless mouse model, 
low extracellular concentrations of calcium ions in the upper epi-
dermis led to exocytosis of lamellar bodies, required for skin barrier 
repair, independent of skin barrier disruption.12
Eczema is associated with a preponderance of Staphylococcus 
aureus and a reduction in microbial diversity.13 Recent work has 
identified a synergistic relationship between the human cathelicidin- 
related antimicrobial peptide LL- 37 and antimicrobial peptides pro-
duced by coagulase- negative staphylococcal species that selectively 
kill Staphylococcus aureus.14 Human LL- 37 activity against some bac-
terial species is decreased by the presence of calcium, but not mag-
nesium, ions.15
The multi- centre Softened Water Eczema Trial (SWET), com-
pleted in 2011, examined the role of water softeners in treating 
children with established, moderate- to- severe eczema and found 
no overall benefit in terms of eczema severity reduction.16 Early 
life is likely to be an important time in the development of eczema, 
particularly as most eczema develops before 2 years of age. Early 
interactions between genes and the environment may be crucial in 
instigating the cycle of inflammation and skin barrier dysfunction 
seen in eczema. Indeed, skin barrier dysfunction in early infancy, as 
measured by transepidermal water loss, is a predictor of subsequent 
eczema risk.17,18 A small pilot randomized controlled double- blind 
crossover trial of 12 patients aged 3– 6 years with mild- moderate 
eczema compared ultra- pure soft water to tap water. After 6 weeks, 
no statistically significant differences in eczema area severity index 
(EASI) or transepidermal water loss (TEWL) were observed between 
the groups, although there was a statistically significant improve-
ment in pruritus as measured by visual analogue score.19 To date, 
there are no studies examining the role of water softeners in the 
prevention of eczema.20
The overall rationale was that by installing a domestic water soft-
ener around the time of birth, the infant would be exposed to soft-
ened water rather than hard water for bathing and that this would 
be less irritating to the skin than hard water and so associated with 
a lower risk of eczema development. Such a study would require a 
large number of participants and before embarking on this it was 
important to determine whether the planned trial recruitment and 
assessment procedures are possible and workable, or whether they 
required adapting or changing.21
This pilot trial built on the experience gained from the SWET 
trial16 and a trial of emollients in early life (Barrier Enhancement for 
Eczema Prevention; BEEP).22 It was a ‘version of the main study that 
is run in miniature to test whether the components of the main study 
can all work together’ (UK National Institute for Health Research23). 
The objective of this pilot trial was, therefore, to determine the fea-
sibility of undertaking a large- scale definitive trial on eczema pre-
vention using a domestic water softener. The trial was not designed 
or powered to definitively answer the question of whether the in-
stallation of a domestic water softener prevents eczema.
2  |  MATERIAL S & METHODS
2.1  |  Study design
This was a multi- centre parallel- group assessor- blinded randomized 
(1:1) controlled pilot trial of an ion- exchange water softener for the 
prevention of eczema in neonates at high risk of developing eczema, 
with an embedded mechanistic study.
2.2  |  Participants
The study recruited pregnant women living in hard water areas 
(CaCO3 >250 mg/L) identified from antenatal services at two public 
hospitals in London, UK: a teaching hospital with secondary and ter-
tiary care maternity services located in urban central London; and a 
community hospital with secondary care maternity services serving a 
mixed urban and rural area in south- west London. Participants were 
recruited between February 2018 and October 2019. Participants 
with a domestic water softener already installed were not eligible. 
Infants needed to be born at term (≥37 weeks’ gestation) and have a 
parent or sibling with a history of doctor- diagnosed atopy (eczema, 
asthma or hay fever) and were excluded if they had a significant in-
flammatory skin disease at birth that would make the detection and 
assessment of eczema difficult, or any other serious health issue that 
would interfere with their ability to participate in the study.
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2.3  |  Intervention
Pregnant women in the intervention arm had a domestic ion- 
exchange water softener (model HV3, Harvey Water Softeners, 
Woking, UK) (Figure 1) installed at their usual place of residence 
after enrolment and before the child's birth. Ion- exchange water 
softeners exchange calcium and magnesium, amongst other divalent 
cations, for monovalent sodium cations, typically reducing down-
stream water hardness to close to zero. The sodium ions come from 
common salt that needs to be topped up every 3– 4 weeks. Standard 
procedure was to soften all water in the home except the drinking 
water tap to avoid the risk of excessive sodium in the drinking water 
being used for infant feed preparation. Unsoftened main drinking 
water was to be delivered through the existing kitchen tap wherever 
possible, or otherwise through an extra (faucet- style) tap installed at 
the side of the kitchen sink. At the end of the study, all participants 
were given the option to purchase the water softener from Harvey 
Water Softeners Ltd. at a reduced price or have it removed (if in the 
intervention arm). The control group had no water softener installed 
and continued to receive their usual domestic hard water supply. 
There were no restrictions on the use of concomitant treatment or 
skincare products for the infant.
2.4  |  Primary and secondary outcomes
The primary purpose of this study was to determine the feasibility 
and acceptability of installing a water softener prior to birth of the 
baby to inform the design of a definitive multi- centre prevention 
RCT. The primary end- point was the proportion of eligible families 
screened who were willing and able to be randomized. Secondary 
feasibility outcomes (proportions, unless stated) were: pregnant 
women approached who agreed to be screened; families eligible 
on screening that could not have a water softener installed (eg due 
to landlord or local authority refusal, technical (plumbing) reasons); 
families randomized that withdrew due to infant ineligibility; fami-
lies in intervention arm who found the intervention acceptable; 
participants in the control arm who became exposed to softened 
water (eg by moving to a new home in a soft water area, or moving 
to a home with an active water softener installed, before the end of 
follow- up); participants that had the water softening unit removed 
or disabled prior to end of follow- up; participants with one or more 
home water samples with hardness >20 mg/L calcium carbonate in 
the intervention arm; participants who withdrew from the trial prior 
to end of follow- up; median number of nights spent away from the 
participant's main home during follow- up; clinical outcome assess-
ments that remained blinded at 4 weeks, 3 and 6 months.
Secondary clinical outcomes: participants with visible eczema 
status (yes/no) recorded at each time point (baseline, 4 weeks, 3 
and 6 months); proportion with patient- reported, doctor- diagnosed 
atopic eczema by 6 months of age; proportion with visible eczema 
according to the UK diagnostic criteria- based photographic proto-
col for visible flexural dermatitis24 (4 weeks, 3 and 6 months); se-
verity of eczema (if present) assessed using the Eczema Area and 
Severity Index (EASI; 4 weeks, 3 and 6 months); patient- reported 
eczema symptoms (Patient- Orientated Eczema Measure – POEM) 
score, monthly from 4 weeks to 6 months. Time to onset of patient- 
reported doctor- diagnosed eczema.
Skin hydration, TEWL and skin surface pH were measured on 
the volar forearm. Skin hydration was measured using a CM 825 
Corneometer (Courage and Khazaka electronic GmbH,). TEWL was 
measured using an AquaFlux AF200 condensing chamber probe 
(Biox Systems Ltd,). Skin surface pH was measured using a PH905 
Skin- Surface- pH probe fitted with a Mettler and Toledo flat sur-
face electrode (Courage and Khazaka electronic GmbH,). Additional 
mechanistic outcomes were also evaluated in a sub- study and the 
analyses of these will be reported separately.
2.5  |  Visit schedule, randomization and blinding
Participants were randomized antenatally at the time of the engi-
neer home visit to receive either a water softener or not, once:
• Antenatal eligibility criteria had been fulfilled;
• Fully informed written consent had been provided; and
• The engineer was satisfied that the softener could technically be 
installed.
The independent online randomization service was provided by 
Guy's and St Thomas’ Biomedical Research Centre (BRC) and used 
the MedSciNet database system. When a patient was recruited, an 
independent BRC administrator who was not involved in patient as-
sessment, obtained the allocation from the online system. This infor-
mation was relayed by telephone to the water softener installation 
engineer so they knew whether to install a softener or not in that 
participant's home. The randomization sequence was designed to 
allocate equally, that is, 1:1 and with randomly permuted blocks to 
prevent the research team guessing the next allocation whilst pro-
viding balance in numbers in the two arms.
Experience from the SWET trial has shown that the effects of 
a functional water softener are too noticeable to allow participants 
F I G U R E  1  Image of a water softener 
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to be blinded.16 Skin examinations and measurements were per-
formed by research team members who were blinded to treatment 
allocation. Participants were encouraged not to disclose allocation. 
Study team members in direct contact with study participants were 
trained on the study protocol and the importance of demonstrating 
equipoise.
An enrolment visit occurred up until 36 weeks gestation to 
allow time for the home installation visit. Eligibility was confirmed 
at this visit. The water softener engineer's home visit occurred up 
until 40 weeks gestation to check the home's suitability for water 
softener installation. If the home was deemed suitable, the engineer 
telephoned the central randomization service to determine the al-
located randomization group. If the participant was randomized to 
the water softener arm, the engineer proceeded to install the water 
softener and provide water sampling materials.
The baseline visit occurred within 1 week of birth. After confirm-
ing infant eligibility criteria and postnatal consent, birth details and 
health status were collected and then neonates had a skin examina-
tion to look for visible flexural dermatitis.
Infants were followed up for up to 6 months from birth with sim-
ilar assessments performed at 1, 3 and 6- month visits. Participants 
who completed the study were asked to complete a short acceptabil-
ity questionnaire. Also, monthly from the birth of the child, a secure 
web- based questionnaire link using the Snap Surveys platform (Snap 
Surveys) was emailed to mothers to determine whether the child had 
received a diagnosis of eczema from a healthcare professional and to 
check current skincare, hygiene, confirm residence/time away from 
the main residence and the infant's general health.
2.6  |  Approvals and registration
This study was given a favourable ethics opinion by the North West— 
Liverpool East Research Ethics Committee (Ref: 17/NW/0661). The 
trial was registered at Clinicaltrials.gov: NCT03270566. The study 
protocol has been published.25
2.7  |  Sample size
This was a pilot study and, therefore, not powered to establish the 
efficacy of the intervention. A total of 80 families (40 per group) was 
judged to provide a sufficiently precise (within 10 percentage points 
for a 95% confidence interval) estimate of the proportion of families 
who are willing to be randomized and who will go on to complete 
the trial. Findings from the Enquiring About Tolerance (EAT) study8 
and the Barrier Enhancement Eczema Prevention (BEEP) feasibility 
study,26 allowed us to make a conservative estimate that approxi-
mately 70% of families screened will have a history of atopy that 
predisposes to a high risk of eczema in their offspring. Of these, 
40%– 60% would be expected to be willing and able to participate. In 
addition, the SWET study reported that 27% of eligible families could 
not participate because their home was not suitable for installation.16
2.8  |  Statistical analysis
As this was a pilot and feasibility trial, the focus was on descriptive 
statistics by randomized group with no hypothesis testing. Binary 
data are presented as frequencies and proportions, continuous data 
as means and SDs and scores as median and interquartile range. 
95% confidence intervals are calculated where possible. The time to 
patient- reported doctor- diagnosed eczema was shown as a Kaplan- 
Meier curve, overall and by group.
3  |  RESULTS
Baseline characteristics are given in Table 1 and were mostly well 
balanced between the randomized groups. The mean overall level 
of water hardness at baseline was 272 mg/L CaCO3 and was similar 
in the two arms. Levels of parental atopy were also similar by study 
arm. A higher proportion of female infants was seen in the water 
softener arm. Just over half of all participants lived in flats and 93% 
lived in urban locations.
3.1  |  Feasibility end- points
A total of 500 pregnant women were approached who expressed an 
interest in the study and were pre- screened, of which 231 (46%, 95% 
CI 42, 51%) were potentially eligible. Of those potentially eligible on 
pre- screening, 154 agreed to consider the study further and had a 
mean gestation of 31 weeks (SD 6 weeks). One hundred and fifty- 
two women then signed an informed consent form at an enrolment 
visit, of these 149 women were fully eligible for the study. Of the 
149 eligible women, 80 (54%, 95% CI: 45, 62%) were randomized, 
the primary end- point of the study. The most common reason for 
ineligibility on pre- screening was no history of atopy (49%) (See 
CONSORT flow diagram, Figure 2). Of the 69 confirmed as eligible, 
but who were not subsequently randomized, 36 (52%) had a home 
that was not suitable for installation of a water softener due to tech-
nical (plumbing) reasons. 11 (16%) participants gave birth before the 
installation visit could take place. Four (5.8%) were unable to have a 
water softener installed due to landlord or local authority refusal or 
subsequently discovered technical problems. Of those randomized, 
two were immediately lost in each group: one in the water softener 
arm where the device could not be installed, and one in the hard 
water control arm who withdrew, leaving 39 in each arm of the trial 
(78 participants). No participants in the intervention arm had the 
water softening unit removed before the end of follow- up.
Potential contamination of the intervention, based on the mean 
(SD) number of nights spent away from the main residence in the 
6 months of follow- up, was 12 (12) and was similar in both groups 
(Table 2).
Out of 708 analysed water samples received from the 39 partici-
pants in the intervention arm, 56 samples (7.9%) were above 20 mg/L 
CaCO3. Sixteen participants (41%) had at least 1 water sample with 
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increased water hardness levels (>20 mg/L CaCO3). No faults were 
found with the units, other than a lack of salt. One participant in the 
intervention arm experienced water hardness exposure >100mg/L 
(104.5 mg/L CaCO3).
By 6 months postpartum, 4 participants in the water softener 
arm and 8 in the control arm were lost to follow- up or withdrew 
(15% attrition). A total of 69/78 (88%) families completed the study 
acceptability questionnaire, all of whom reported that they found 
the study acceptable and 67/69 (97%) said that they would take part 
in the same study again.
3.2  |  Clinical end- points
At 6 months of age, 27/67 infants (40%) developed visible eczema 
and 15/36 infants (42%) had parent- reported doctor- diagnosed 
eczema. Of those with parent- reported doctor- diagnosed eczema, 
13/15 (87%) also had visible eczema on examination, however, only 
68% (13/19) of those with visible eczema on examination had cor-
responding parent- reported doctor- diagnosed eczema. Blinding 
was maintained for 96% of completed assessments at 4 weeks and 
3 months and 100% at 6 months.
TA B L E  1  Baseline characteristics of the infant trial population
Characteristic of the infant Water softener % (n/N) No water softener % (n/N)
Number in group 40a 40b
Sex Female 64% (25/39) 46% (18/39)
Ethnicity White British 33% (13/39) 33% (13/39)
Other White 15% (6/39) 18% (7/39)
White and Asian 18% (7/39) 15% (6/39)
Other Mixed 15% (6/39) 15% (6/39)
Chinese 10% (4/39) 5.1% (2/39)
Other 7.7% (3/39) 13% (5/39)
Birth history
Birth weight, g, mean (SD) 3513.4 (446.8) 3429.5 (399.1)
Mode of delivery Vaginal 67% (26/39) 72% (28/39)
C- section 33% (13/39) 28% (11/39)
Born in a bathing pool 0 (0/26) 0 (0/28)
Maternal antibiotic exposure during pregnancy 26% (10/39) 21% (8/39)
Family atopy status (self- reported) 100% (39/39) 100% (39/39)
Maternal
Eczema 46% (18/39) 49% (19/39)
Atopy* 82% (32/39) 82% (32/39)
Paternal
Eczema 36% (14/39) 21% (8/39)
Atopy* 59% (23/39) 62% (24/39)
Sibling
Eczema 21% (8/39) 18% (7/39)
Atopy* 21% (8/39) 18% (7/39)
Home environment
Property type House 36% (14/39) 46% (18/39)
Flat 64% (25/39) 54% (21/39)
Home location type Urban 92% (36/39) 92% (36/39)
Rural non- farm 7.7% (3/39) 7.7% (3/39)
Domestic water CaCO3 mg/L, mean (SD) 274.6 (25.0) N = 40 269.5 (17.5) (N = 38)
Skin physiological parameters
Skin surface hydration, arbitrary units, mean (SD) 17.9 (8.1) (n = 31) 17.4 (8.1) (n = 30)
Transepidermal water loss (g·m– 2·h– 1 mean (SD) 13.1 (2.8) (n = 27) 14.6 (4.2) (n = 28)
Skin pH, mean (SD) 5.7 (0.6) (n = 30) 5.9 (0.7) (n = 28)
Note: *Eczema, asthma or hay fever.
aSoftener could not be installed following randomization of one participant.
bOne participant withdrew consent immediately after randomization.
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A lower proportion of infants in the water softener arm (6/17, 
35%) had parent- reported, doctor- diagnosed atopic eczema by 
6 months of age compared to those in the control arm (9/19, 47%) ex-
posed to hard water (difference −12%, 95% CI −44, 20%). This mag-
nitude of effect was also observed in the proportion of infants with 
visible eczema by 6 months of age (difference −15%, 95% CI −38, 
8.3%) (Table 3). Time to onset of parent- reported doctor- diagnosed 
eczema was similar in the two arms (Figure 2) and Figure 3. Trends 
in EASI and POEM scores were generally consistent. Median EASI 
scores beyond 4 weeks were lower in the water softener arm than 
the control arm. Median POEM scores beyond 4 weeks were lower 
in the water softener arm than the control arm (Table 3).





Delivered before installaon visit (n=11)
Unable to get landlord permission (n=4)
Other reasons (n=6)
Assessed for visible eczema at 1 m (n=39)
Assessed for visible eczema at 3 m (n=37)
Assessed for visible eczema at 6 m (n=36)
Did not complete (n=4)
Lost to follow up (n=3)
Withdrawal by parcipant (n=1)
Allocated to intervention (n=40)
Intervention not received – softener could not 
be installed (n=1) 
Did not complete (n=8)
Lost to follow up (n=6)
Withdrawal by parcipant (n=1)
Other (Parcipant moved to another
country) (n=1)
Allocated to intervention (n=40)
Withdrew consent after allocation (n=1)
Assessed for visible eczema at 1 m (n=35)
Assessed for visible eczema at 3 m (n=34)






Excluded  (n=269)* 
No history of atopy (n=133)
Not in a hard water area (n=59)
Unable to get landlord consent (n=10)
Planning to move (n=34)




Pre-screened prior to eligibility
assessment (n=500)
Potenally eligibility on pre-
screen (n=231)
Potenally eligible but not willing or able 
to proceed (n=82)
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4  |  DISCUSSION
This pilot study assessed the feasibility of installing home water sof-
teners for the prevention of eczema in high- risk neonates. Overall, 
around half of eligible pregnant women were willing and able to be 
randomized. This is consistent with the proportion (42%) of eligible 
families who were randomized into the Barrier Enhancement Eczema 
Prevention (BEEP) pilot study26 that informed the design of the full- 
scale BEEP study. The most common reason for failure to proceed 
to randomization was that the participant's home was not suitable 
for the installation of a water softener. Potential contamination of 
the intervention was low, with a low number of nights (mean 12 
TA B L E  2  Feasibility outcomes
Outcome Estimate (95% CI) (n/N)
Proportion of eligible families screened who are willing and able to be randomized (95% CI) 54% (45, 62%) (80/149)
Proportion of pregnant women approached who agree to be screened (95% CI) 45% (41, 49%) (225/500)
Proportion of families eligible on screening that cannot have a water softener installed (eg due to landlord or local 
authority refusal, technical (plumbing) reasons) (95% CI)
28% (21, 35%) (41/149)
Proportion of families randomized that withdraw due to infant ineligibility 0% (0/80)
Proportion of families in intervention arm who found the study acceptable 100% (36/36)
Proportion of participants that have the water softening unit removed or disabled prior to end of follow- up 0% (0/39)
Proportion of water samples with hardness >20 mg/L calcium carbonate in the intervention arm 7.9% (56/708)
Proportion of subjects in the intervention arm with at least 1 water sample with hardness >20 mg/L 
calcium carbonate
41% (16/39)
Proportion of participants that withdraw from the trial prior to end of follow- up (95% CI) 15% (8.9, 25%) (12/78)
Mean (SD) number of nights spent away from the participant's main home during follow- up 12 (12) (n = 36)
Proportion of clinical outcome assessments that have remained blinded at 4 weeks, 3 & 6 months (95% CI), [N#]:
• 4 weeks 96% (88, 99%) (72/75)
• 3 months 96% (88, 98%) (69/72)
• 6 months 100% (69/69)
Abbreviations: [N#], Number of assessments completed; CI, Confidence interval; N, Number of water samples received; SD, standard deviation.
TA B L E  3  Clinical outcomes
Outcome Water softener (n/N) No water softener n(n/N)
Difference (water softener 
– hard water) (95% CI)*
Parent- reported, doctor- diagnosed atopic eczema by 
6 months of age,
35% (6/17) 47% (9/19) −12% (−44, 20%) (n = 36)
Time to onset of patient- reported doctor- diagnosed 
eczema (weeks), mean (SD)
24.0 (4.9) (n = 37) 23.5 (5.7) (n = 34) 0.55 (−1.9, 3.1) (n = 71)
Visible eczema at 4 weeks 2.6% (1/39) 17% (6/35) −15% (−28, −1.1%) (n = 74)
Visible eczema at 3 months of age 24% (9/37) 8.8% (3/34) −16% (−1.29, 32%) (n = 71)
Visible eczema at 6 months of age, 8.3% (3/36) 28% (9/32) −20% (−38, −1.8%) (n = 68)
Visible eczema by 6 months of age 33% (12/36) 48% (15/31) −15% (−38, 8.3%) (n = 67)
EASI at 4 weeks, median (IQR)# 17 (0) (n = 1) 1.2 (1.8) (n = 5) 16 (n = 6)
EASI at 3 months, median (IQR)# 0.8 (0.4) (n = 9) 1.3 (12.5) (n = 3) −0.5 (n = 12)
EASI at 6 months, median (IQR)# 0.8 (0.4) (n = 2) 2.0 (1.0) (n = 9) −1.2 (n = 11)
POEM at 4 weeks, median (IQR)# 16 (0) (n = 1) 10 (0) (n = 1) 6 (n = 2)
POEM at 2 months, median (IQR)# 1.0 (0) (n = 1) 4.5 (1.0) (n = 2) −3.5 (n = 3)
POEM at 3 months, median (IQR)# 4.0 (0) (n = 6) 8.5 (9.5) (n = 4) −4.5 (n = 10)
POEM at 4 months, median (IQR)# 3.0 (1.0) (n = 3) 16 (15) (n = 2) −13 (n = 5)
POEM at 5 months, median (IQR)# 2.0 (4.0) (n = 2) 8.5 (8.5) (n = 8) −6.5 (n = 10)
POEM at 6 months, median (IQR)# 1.0 (1.0) (n = 2) 10 (9.0) (n = 7) −9 (n = 9)
*Only calculated for differences in means.
#Only completed when the mother reported that the infant had eczema.
EASI— Eczema Area and Severity Index, IQR— interquartile range, N: total number of participants, [N] number of participants with complete data, 
POEM— patient- oriented eczema measure, SD standard deviation.
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nights, SD 12) on average spent away from the main residence over 
the 6 months follow- up period. 41% (n = 39) of participants in the 
water softener arm had at least one water sample out of the softer 
water range (>20 mg/L CaCO3) with a low proportion of total water 
samples (7.9%, n = 708) out of the soft water range, despite the need 
for participants to top- up the unit with salt.
These findings suggest that the current study design could be 
scaled- up in a fully powered RCT prevention study. The question 
is then how large such a study would need to be. Approximately 
one- third of infants developed eczema over the first 6 months of 
life in this high- risk population, and this is consistent with other 
estimates in the literature.8 There was some discordance between 
parent- reported doctor- diagnosed eczema and those with visible ec-
zema on skin examination, the latter detecting more ‘cases’ than the 
former, suggesting that both end- points would probably need to be 
measured in a future study.
This study is the first randomized controlled trial testing the ef-
fect of water softeners on infant eczema providing data on the likely 
magnitude of effect, and therefore, sample size requirements for an 
adequately statistically powered prevention study. Based on the ob-
served difference in visible eczema of 15% and attrition of 16%, the 
sample size requirement for a study with 80% power is likely to be 
>860 participants, allowing for attrition. Based on the data gener-
ated in this study, roughly 6 pregnant women had to be approached 
F I G U R E  3  Kaplan- Meier curves for 
time to onset of parent- reported doctor- 
diagnosed eczema 
(A) Overall
(B) By treatment arm
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and pre- screened for every randomized participant, suggesting 
around 5200 pregnant women would need to be approached about 
the study.
There were 27 infants who developed visible eczema by 
6 months. The magnitude of the point estimate of the relative 
risk (softened water/control) is 0.68 (95% CI 0.38, 1.2), which is 
consistent with the magnitude of risk reduction that might be ex-
pected by softening water based on the increased odds identified 
with hard water exposure in children in a recent systematic review 
and meta- analysis conducted by our group (OR 1.28).20 However, 
there is uncertainty around the relative risk and, as observed in 
studies of emollient use for the prevention of eczema, encour-
aging findings from pilot data may not hold in a fully powered 
study.26,27 Additionally, in the absence of longer- term follow- up, 
there is the possibility that use of a water softener in early life 
simply delays the onset of eczema rather than preventing it. Given 
that approximately 80% of eczema cases occur before 2 years of 
age, this would seem an appropriate follow- up period for a defin-
itive prevention trial.
Infants in the water softener arm who developed eczema ap-
peared to have lower severity scores, both in terms of clinician- 
(EASI) and parent- assessed (POEM) measures, compared to those in 
the hard water arm. Lower POEM scores were also seen with the 
addition of a water softener to usual care versus usual care alone in 
the SWET trial. However, in this study as with the SWET trial, there 
is a high risk of biased POEM assessments as parents were unblinded 
to the intervention status.
5  |  CONCLUSIONS
In summary, the results from this pilot RCT indicate that a definitive 
RCT to assess the prevention of atopic eczema in high- risk infants 
may be feasible in a mixed urban and suburban setting in England. 
However, many clinical sites would be needed to recruit enough 
pregnant women over a 1 year period. The outcome, eczema, is a 
binary variable and as such requires a considerably larger sample 
size to detect differences. Overall, pregnant women found the study 
design acceptable. Adjustments to the study design may help to re-
duce the proportion of eligible pregnant women who do not go on 
to be randomized, in particular, around the timing and organization 
of the water softener installation visit and so improve the efficiency 
of the trial.
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